日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab

接受帕博利珠单抗抗PD-1检查点抑制剂免疫治疗的转移性黑色素瘤患者，在初始病情稳定的患者中，长期临床疗效如何？

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-025-03048-8
Noringriis, Inge Mansfield; Donia, Marco; Madsen, Kasper; Schmidt, Henrik; Haslund, Charlotte Aaquist; Bastholt, Lars; Svane, Inge Marie; Ellebaek, Eva
免疫/内分泌
PD-1
黑色素瘤
发表日期：2025
文献求助 收藏

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

BRAF/MEK抑制剂治疗转移性黑色素瘤患者的心脏毒性：真实世界发生率、危险因素和可逆性分析

期刊:Acta Oncologica
影响因子:2.2
doi:10.2340/1651-226X.2025.42567
Oddershede, Jonas K; Meklenborg, Ida K; Bastholt, Lars; Guldbrandt, Louise M; Schmidt, Henrik; Friis, Rasmus B
BRAF
黑色素瘤
毒理研究
发表日期：2025
文献求助 收藏

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

凡德他尼用于治疗对放射性碘疗法无效的局部晚期或转移性分化型甲状腺癌

期刊:Endocrine-Related Cancer
影响因子:4.6
doi:10.1530/ERC-23-0354
Brose, Marcia S; Capdevila, Jaume; Elisei, Rossella; Bastholt, Lars; Führer-Sakel, Dagmar; Leboulleux, Sophie; Sugitani, Iwao; Taylor, Matthew H; Wang, Zhuoying; Wirth, Lori J; Worden, Francis P; Bernard, John; Caferra, Paolo; Colzani, Raffaella M; Liu, Shiguang; Schlumberger, Martin
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2024
文献求助 收藏

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)

尼达尼布作为二线治疗方案，用于一线治疗后进展的分化型或髓样甲状腺癌患者的安全性和有效性。欧洲癌症研究与治疗组织内分泌工作组开展的一项随机II期研究（方案1209-EnTF）。

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2024.1403687
Leboulleux, Sophie; Kapiteijn, Ellen; Litière, Saskia; Schöffski, Patrick; Godbert, Yann; Rodien, Patrice; Jarzab, Barbara; Salvatore, Domenico; Zanetta, Sylvie; Capdevila, Jaume; Bastholt, Lars; De La Fouchardiere, Christelle; Lalami, Yassine; Bardet, Stéphane; Cornélis, Frank; Dedecjus, Marek; Links, Thera; Sents, Ward; Schlumberger, Martin; Locati, D Laura; Newbold, Katie
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2024
文献求助 收藏

Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study

接受辅助PD-1抑制剂治疗的III/IV期黑色素瘤切除术后患者免疫相关甲状腺不良事件的发生频率和特征：一项全国性队列研究

期刊:Supportive Care in Cancer
影响因子:3
doi:10.1007/s00520-024-08445-y
Christensen, Stine K; Winther, Mette L; Laursen, Ida J; Madsen, Freja S; Brink, Carsten; Brix, Thomas H; Ellebaek, Eva; Svane, Inge Marie; Hansen, Frederikke S; Haslund, Charlotte; Laursen, Olivia K; Schmidt, Henrik; Larsen, Ida D; Bastholt, Lars; Ruhlmann, Christina H
黑色素瘤
PD-1
免疫/内分泌
发表日期：2024
文献求助 收藏

Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021: A National Observational Cohort Study of 25 720 Patients With Stage IA to IV Melanoma

2008-2021年丹麦黑色素瘤患者分期特异性复发和死亡风险：一项纳入25720例IA期至IV期黑色素瘤患者的全国性观察性队列研究

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2023.3256
Helvind, Neel M; Brinch-Møller Weitemeyer, Marie; Chakera, Annette H; Hendel, Helle W; Ellebæk, Eva; Svane, Inge Marie; Kjærskov, Mette W; Bojesen, Sophie; Skyum, Helle; Petersen, Søren K; Bastholt, Lars; Johansen, Christoffer; Bidstrup, Pernille E; Hölmich, Lisbet R
黑色素瘤
发表日期：2023
文献求助 收藏

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Selumetinib 联合辅助放射性碘治疗高危分化型甲状腺癌患者：一项 III 期随机安慰剂对照试验 (ASTRA)

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.00714
Ho, Alan L; Dedecjus, Marek; Wirth, Lori J; Tuttle, R Michael; Inabnet, William B 3rd; Tennvall, Jan; Vaisman, Fernanda; Bastholt, Lars; Gianoukakis, Andrew G; Rodien, Patrice; Paschke, Ralf; Elisei, Rossella; Viola, David; So, Karen; Carroll, Danielle; Hovey, Tina; Thakre, Bhavana; Fagin, James A
甲状腺癌
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2022
文献求助 收藏

Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial

患者报告结局对免疫检查点抑制剂治疗期间症状监测的影响：一项随机对照试验中黑色素瘤患者的健康相关生活质量

期刊:Journal of Patient-Reported Outcomes
影响因子:2.9
doi:10.1186/s41687-022-00414-5
Tolstrup, Lærke K; Pappot, Helle; Bastholt, Lars; Möller, Sören; Dieperink, Karin B
黑色素瘤
免疫/内分泌
发表日期：2022
文献求助 收藏

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

凡德他尼治疗进展期和症状性甲状腺髓样癌的疗效和安全性：ZETA试验的事后分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.19.02790
Kreissl, Michael C; Bastholt, Lars; Elisei, Rossella; Haddad, Robert; Hauch, Ole; Jarząb, Barbara; Robinson, Bruce; Colzani, Raffaella; Foster, Meredith; Weiss, Richard; Schlumberger, Martin
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2020
文献求助 收藏

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

一项比较伊匹木单抗10 mg/kg与3 mg/kg治疗晚期黑色素瘤患者的III期临床试验，5年随访总生存期结果显示，患者总体生存率存在差异。

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2019-000391
Ascierto, Paolo Antonio; Del Vecchio, Michele; Mackiewicz, Andrzej; Robert, Caroline; Chiarion-Sileni, Vanna; Arance, Ana; Lebbé, Céleste; Svane, Inge Marie; McNeil, Catriona; Rutkowski, Piotr; Loquai, Carmen; Mortier, Laurent; Hamid, Omid; Bastholt, Lars; Dreno, Brigitte; Schadendorf, Dirk; Garbe, Claus; Nyakas, Marta; Grob, Jean-Jacques; Thomas, Luc; Liszkay, Gabriella; Smylie, Michael; Hoeller, Christoph; Ferraresi, Virginia; Grange, Florent; Gutzmer, Ralf; Pikiel, Joanna; Hosein, Fareeda; Simsek, Burcin; Maio, Michele
黑色素瘤
发表日期：2020
文献求助 收藏